Government-Owned Inventions; Availability for Licensing, 35922-35924 [06-5579]
Download as PDF
<![CDATA[
35922
Federal Register / Vol. 71, No. 120 / Thursday, June 22, 2006 / Notices
Responses
per
respondent
Est. number of
respondents
Data collection
Burden per
response *
Application to Medical Staff ......................................................................
Reference Letter .......................................................................................
Reappointment Request ...........................................................................
Ob-Gyn Privileges ....................................................................................
Internal Medicine ......................................................................................
Surgery Privileges ....................................................................................
Psychiatry Privileges ................................................................................
Anesthesia Privileges ...............................................................................
Dental Privileges .......................................................................................
Optometry Privileges ................................................................................
Psychology Privileges ...............................................................................
Audiology Privileges .................................................................................
Podiatry Privileges ....................................................................................
Radiology Privileges .................................................................................
Pathology Privileges .................................................................................
600
1800
200
25
387
23
18
16
128
21
23
6
6
9
3
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Total ...................................................................................................
3,265
........................
1.00
0.33
1.00
1.00
1.00
1.00
1.00
1.00
0.33
0.33
0.17
0.08
0.08
0.33
0.33
Total annual
burden hrs.
(60 mins) ....
(20 mins) ....
(60 mins) ....
(60 mins) ....
(60 mins) ....
(60 mins) ....
(60 mins) ....
(60 mins) ....
(20 mins) ....
(20 mins) ....
(10 mins) ....
(5 mins) ......
(5 mins) ......
(20 mins) ....
(20 mins) ....
600.0
594.0
200.0
25.0
387.0
23.0
18.0
16.0
42.2
6.9
3.9
0.48
0.48
2.9
.99
.............................
1,920.85
* For ease of understanding, burden hours are provided in actual minutes.
wwhite on PROD1PC61 with NOTICES
There are no capital costs, operating
costs and/or maintenance costs to
respondents.
Request for Comments: Your written
comments and/or suggestions are
invited on one or more of the following
points: (a) Whether the information
collection activity is necessary to carry
out an agency function; (b) whether the
agency processes the information
collected in a useful and timely fashion;
(c) the accuracy of public burden
estimate (the estimated amount of time
needed for individual respondents to
provide the requested information); (d)
whether the methodology and
assumptions used to determine the
estimate are logical; (e) ways to enhance
the quality, utility, and clarity of the
information being collected; and (f)
ways to minimize the public burden
through the use of automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Send Comments and Requests for
Further Information: For the proposed
collection or requests to obtain a copy
of the data collection instrument(s) and
instructions to: Mrs. Christina Rouleau,
IHS Reports Clearance Officer, 801
VerDate Aug<31>2005
19:08 Jun 21, 2006
Jkt 208001
Thompson Avenue, TMP Suite 450,
Rockville, MD 20852, call non-toll free
(301) 443–5938, send via facsimile to
(301) 443–2316, or send your e-mail
requests, comments, and return address
to: crouleau@hqe.ihs.gov.
Comment Due Date: Your comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: June 15, 2006.
Robert G. McSwain,
Deputy Director, Indian Health Service.
[FR Doc. 06–5574 Filed 6–21–06; 8:45 am]
BILLING CODE 4165–16–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
Government-Owned Inventions;
Availability for Licensing
Beta-Amyloid PET Imaging Agents
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
Description of Technology: Available
for licensing and commercial
development are two novel classes of
compounds useful as radioligands for in
vivo imaging of beta-amyloid (Aβ)
peptides and plaques in humans.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
E:\FR\FM\22JNN1.SGM
22JNN1
Beta-amyloid peptide deposition in
the brain is a pathological feature of
Alzheimer’s disease (AD). Early
detection of beta-amyloid load in
patients with suspected AD is vital to
initiating early treatment, which can
improve cognitive function and quality
of life for many patients.
The invention describes novel
derivatives of
imidazopyridinylbenzeneamine (IMPY)
and benzothizolylbenzeneamine (BTA),
which demonstrate high in vitro binding
affinity to human beta-amyloid. The
difference between existing IMPY
compounds and the novel derivatives is
the substitution of an aryl halide with
an aryl thioether group and replacement
of a sulfur group of the pyridine ring
with a nitrogen group. The new classes
of compounds have the potential of
providing improved amyloid imaging
agents for Positron Emission
Tomography (PET) with higher
specificity for amyloid, low background
noise, better entry into the brain and
improved labeling efficiency.
In addition to the novel compounds,
the invention also includes: (1) A new
method of synthesizing the IMPY
derivatives, using palladium as a
catalyst, (2) methods of imaging betaamyloid deposits in the brain by in vivo
PET, magnetic reasonance imaging
(MRI) and other imaging methods
involving the use of these compounds,
and (3) and methods of labeling these
compounds with radiotracers ([11-C]
and [18-F]).
Inventors: Lisheng Cai (NIMH), Victor
Pike (NIMH), and Robert Innis (NIMH).
VerDate Aug<31>2005
19:08 Jun 21, 2006
Jkt 208001
Publications:
1. Nichols L, Pike VW, Cai L, Innis
RB. (2006) ‘‘Imaging and In Vivo
Quantitation of beta-Amyloid: An
Exemplary Biomarker for Alzheimer’s
Disease?,’’ Biol Psychiatry. [E-pub ahead
of print].
2. Toyoma H, et al. (2006) ‘‘PET
imaging of brain with the beta-amyloid
probe, [11C]6-OH-BTA-1, in a transgenic
mouse model of Alzheimer’s disease,’’
Eur J Nucl Med Mol Imaging. 32(5),
593–600.
3. Cai L, et al. (2004) ‘‘Synthesis and
Evaluation of Two18 F-Labeled 6-Iodo-2(4′-N,Ndimethylamino)phenylimidazo[1,2a]pyidine Derivatives as Prospective
Radioligands for -Amyloid in
Alzheimer’s Disease,’’ J Med Chem, 47
(9), 2208–2218.
Patent Status: U.S. Provisional
Application filed 21 Apr 2006 (HHS
Reference No. E–156–2006/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Michael
Shmilovich; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NIMH Molecular Imaging Branch is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
Beta-Amyloid PET Imaging Agents.
Please contact Suzanne Winfield at
winfiels@mail.nih.gov for more
information.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
35923
Carbohydrate-Encapsulated Quantum
Dots for Cell-Specific Biological
Imaging
Description of Technology: Available
for licensing is intellectual property
covering carbohydrate-encapsulated
quantum dots (QD) for use in medical
imaging and methods of making the
same. Certain carbohydrates, especially
those included on tumor glycoproteins
are known to have affinity for certain
cell types. One notable glycan used in
the present invention is the ThomsenFreidenreich disaccharide (Galb13GalNAc) that is readily detectable in
90% of all primary human carcinomas
and their metastases. These glycans can
be exploited for medical imaging.
Quantum Dots (QDs) are semiconductor
nanocrystals (CdSe or CdTe) with
detectable luminescent properties.
Encapsulating luminescent QDs with
target-specific glycans permits efficient
imaging of the tissue to which the
glycans bind with high affinity.
Accurate imaging of diseased cells (e.g.,
primary and metastatic tumors) is of
primary importance in disease
management. The inventors describe a
method for enhancing the luminescence
of carbohydrate-encapsulated QDs by
addition of specific functional units in
a novel synthesis of hybrid CdTe-based
core-shell semiconductor nanocrystals.
Inventors: Joseph Barchi and Sergey
Svarovsky (NCI).
Patent Status: PCT Application No.
PCT/US03/34897 filed 05 Nov 2003
(HHS Reference No. E–325–2003/0–
PCT–01).
E:\FR\FM\22JNN1.SGM
22JNN1
EN22JN06.002</GPH>
wwhite on PROD1PC61 with NOTICES
Federal Register / Vol. 71, No. 120 / Thursday, June 22, 2006 / Notices
35924
Federal Register / Vol. 71, No. 120 / Thursday, June 22, 2006 / Notices
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Michael
Shmilovich; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of
Medicinal Chemistry is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize carbohydrateencapsulated quantum dots. Please
contact Dr. Melissa Maderia by phone:
(301) 846–5465 or fax: (301) 846–6820
or e-mail: maderiam@mail.nih.gov for
more information.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
wwhite on PROD1PC61 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section 552b(c)(4)
and 552b(c)(6), Title 5 U.S.C., as
amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Mental Health Special Emphasis Panel, HIV
and Psychiatric Comorbidities.
Date: July 10, 2006.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn Chevy Chase, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Peter J. Sheridan, PhD,
Scientific Review Administrator, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6142, MSC 9606,
Bethesda, MD 20892–9606. 301–443–1513.
psherida@mail.nih.gov.
Jkt 208001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Center for Scientific Review; Amended
Notice of Meeting
BILLING CODE 4140–01–M
19:08 Jun 21, 2006
BILLING CODE 4140–01–M
National Institutes of Health
Dated: June 14, 2006.
David R. Sadowski,
Acting Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. 06–5579 Filed 6–21–06; 8:45 am]
VerDate Aug<31>2005
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: June 14, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–5571 Filed 6–21–06; 8:45 am]
Notice is hereby given of a change in
the meeting of the Electrical Signaling,
Ion Transport, and Arrhythmias Study
Section, June 22, 2006, 8 a.m. to June
23, 2006, 5 p.m., Georgetown Suites,
1111 30th Street, NW., Washington, DC
20007 which was published in the
Federal Register on May 11, 2006, 71
FR 27505–27507.
The meeting will be held at the
Georgetown Suites, 1000 29th Street,
NW., Washington, DC 20007. The
meeting dates and time remain the
same. The meeting is closed to the
public.
Dated: June 13, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–5572 Filed 6–21–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Psychiatric
Genetics Collaborative R01’s
Date: June 30, 2006.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Watergate, 2650 Virginia
Avenue, NW., Washington, DC 20037.
Contact Person: Cheryl M. Corsaro, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2204,
MSC 7890, Bethesda, MD 20892, (301) 435–
1045, corsaroc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Bacterial
Vaginosis—A Clinical Study.
Date: June 30, 2006.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Robert Freund, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3200,
MSC 7848, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, EMNR
Special Emphasis Panel SBIR.
Date: July 6–7, 2006.
Time: 7 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Krish Krishnan, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6164,
MSC 7892, Bethesda, MD 20892, (301) 435–
1041, krishnak@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Review of
Member Conflict Applications.
Date: July 7, 2006.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: Mark P. Rubert, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1775, rubertm@csr.nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group, AIDS
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 71, Number 120 (Thursday, June 22, 2006)]
[Notices]
[Pages 35922-35924]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-5579]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Beta-Amyloid PET Imaging Agents
Description of Technology: Available for licensing and commercial
development are two novel classes of compounds useful as radioligands
for in vivo imaging of beta-amyloid (A[beta]) peptides and plaques in
humans.
[[Page 35923]]
[GRAPHIC] [TIFF OMITTED] TN22JN06.002
Beta-amyloid peptide deposition in the brain is a pathological
feature of Alzheimer's disease (AD). Early detection of beta-amyloid
load in patients with suspected AD is vital to initiating early
treatment, which can improve cognitive function and quality of life for
many patients.
The invention describes novel derivatives of
imidazopyridinylbenzeneamine (IMPY) and benzothizolylbenzeneamine
(BTA), which demonstrate high in vitro binding affinity to human beta-
amyloid. The difference between existing IMPY compounds and the novel
derivatives is the substitution of an aryl halide with an aryl
thioether group and replacement of a sulfur group of the pyridine ring
with a nitrogen group. The new classes of compounds have the potential
of providing improved amyloid imaging agents for Positron Emission
Tomography (PET) with higher specificity for amyloid, low background
noise, better entry into the brain and improved labeling efficiency.
In addition to the novel compounds, the invention also includes:
(1) A new method of synthesizing the IMPY derivatives, using palladium
as a catalyst, (2) methods of imaging beta-amyloid deposits in the
brain by in vivo PET, magnetic reasonance imaging (MRI) and other
imaging methods involving the use of these compounds, and (3) and
methods of labeling these compounds with radiotracers ([11-C] and [18-
F]).
Inventors: Lisheng Cai (NIMH), Victor Pike (NIMH), and Robert Innis
(NIMH).
Publications:
1. Nichols L, Pike VW, Cai L, Innis RB. (2006) ``Imaging and In
Vivo Quantitation of beta-Amyloid: An Exemplary Biomarker for
Alzheimer's Disease?,'' Biol Psychiatry. [E-pub ahead of print].
2. Toyoma H, et al. (2006) ``PET imaging of brain with the beta-
amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of
Alzheimer's disease,'' Eur J Nucl Med Mol Imaging. 32(5), 593-600.
3. Cai L, et al. (2004) ``Synthesis and Evaluation of Two\18\ F-
Labeled 6-Iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyidine
Derivatives as Prospective Radioligands for -Amyloid in Alzheimer's
Disease,'' J Med Chem, 47 (9), 2208-2218.
Patent Status: U.S. Provisional Application filed 21 Apr 2006 (HHS
Reference No. E-156-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NIMH Molecular Imaging
Branch is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize Beta-Amyloid PET Imaging Agents. Please contact Suzanne
Winfield at winfiels@mail.nih.gov for more information.
Carbohydrate-Encapsulated Quantum Dots for Cell-Specific Biological
Imaging
Description of Technology: Available for licensing is intellectual
property covering carbohydrate-encapsulated quantum dots (QD) for use
in medical imaging and methods of making the same. Certain
carbohydrates, especially those included on tumor glycoproteins are
known to have affinity for certain cell types. One notable glycan used
in the present invention is the Thomsen-Freidenreich disaccharide
(Galb1-3GalNAc) that is readily detectable in 90% of all primary human
carcinomas and their metastases. These glycans can be exploited for
medical imaging. Quantum Dots (QDs) are semiconductor nanocrystals
(CdSe or CdTe) with detectable luminescent properties. Encapsulating
luminescent QDs with target-specific glycans permits efficient imaging
of the tissue to which the glycans bind with high affinity. Accurate
imaging of diseased cells (e.g., primary and metastatic tumors) is of
primary importance in disease management. The inventors describe a
method for enhancing the luminescence of carbohydrate-encapsulated QDs
by addition of specific functional units in a novel synthesis of hybrid
CdTe-based core-shell semiconductor nanocrystals.
Inventors: Joseph Barchi and Sergey Svarovsky (NCI).
Patent Status: PCT Application No. PCT/US03/34897 filed 05 Nov 2003
(HHS Reference No. E-325-2003/0-PCT-01).
[[Page 35924]]
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael Shmilovich; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Laboratory of Medicinal Chemistry is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
carbohydrate-encapsulated quantum dots. Please contact Dr. Melissa
Maderia by phone: (301) 846-5465 or fax: (301) 846-6820 or e-mail:
maderiam@mail.nih.gov for more information.
Dated: June 14, 2006.
David R. Sadowski,
Acting Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. 06-5579 Filed 6-21-06; 8:45 am]
BILLING CODE 4140-01-M
